We are driven to make a difference for patients and those who care for them.

At the heart of everything we do at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.

We are pioneering a new field of medicine focused on controlling the expression of genes. The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it changes the function of a cell, leading to disease. Because gene expression is fundamental to the function of all cells, we believe our pioneering approach has potential to create medicines that provide patients with a range of diseases the opportunity to live longer and enjoy a better quality of life.

We are currently advancing three programs in clinical development: tamibarotene in defined subsets of patients with myelodysplastic syndrome and acute myeloid leukemia; SY-2101 in patients with acute promyelocytic leukemia; and SY-5609 in patients with select solid tumors and blood cancers. In addition, we have multiple programs in earlier stages of research for cancer, as well as genetic diseases, for which there is a dire need for better medicines.

We invite you to learn more about our programs and ongoing clinical trials, as well as to explore a select list of resources for these diseases.

Nancy Simonian, M.D.
Chief Executive Officer of Syros

Nancy Simonian, M.D.
Chief Executive Officer of Syros